InsidersTradesSigma
Track the Ernexa Therapeutics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €9.2m. The latest transaction was reported on 11 June 2025 (Acquisition). Among the most active insiders: Cherington Charles. The full history is accessible without an account.
Analysts rate Ernexa Therapeutics Inc. Strong Buy (bullish), based on 1 analysts. Average price target: US$30.00.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Ernexa Therapeutics Inc. is a company focused on developing innovative therapeutic treatments. It is listed on the XNAS market.